For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

In the world of oncology drug development, the standard playbook is simple: race to earlier lines of treatment, where patient ...

Eli Lilly will not seek a broad FDA approval for a combination of the company’s oral SERD med Inluriyo and CDK4/6 inhibitor ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...

Eli Lilly and Co said on Monday it will buy Loxo Oncology Inc for $8 billion, an expensive bet on a pipeline of cancer drugs that target rare genetic mutations and the biggest acquisition in Lilly’s ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly and Company and Loxo Oncology, Inc announced a definitive agreement for Lilly to acquire Loxo Oncology for US$ 235.00 per share in cash, or approximately US$ 8.0 billion. Loxo Oncology is a ...